Source: Arabic.Net – Jamal Nazi
The US Food and Drug Administration has granted the FDA a license to use blood purification systems as part of emergency treatments for adult patients with HIV. Corona “Covid 19”.
The method may be used for patients over 18 years of age or older, who have been admitted to intensive care units after suffering respiratory failure.
According to a statement from the FDA, these systems reduce, through the process of blood filtering, the amount of cytokines and triggers of inflammation by clearing the patient’s blood and returning it to the patient again. The purification system filters the proteins that are high in the blood of the infected patients, and that accompany the patients’ injury with a so-called “cytokine storm”, which can lead to high levels of suffering from severe inflammation, shock and respiratory failure, followed by a failure in the rest of the body, leading to The death of a sick Covid-19.
“We continue to work in all sectors to accelerate the development of many potential innovative preventive and curative methods by facilitating access for patients in emergency situations, to the maximum extent possible medical care and support in evaluating potential treatments,” said Stephen Hahn, FDA commissioner.
“The decision to authorize the use of blood purifiers is part of efforts to provide more options for treating patients in intensive care units, to help reduce lethal disease in patients,” Han added. “FDA teams will continue to conduct round-the-clock reviews of all medical products in order to accelerate the provision of Treatments to help combat this devastating disease. “
It should be noted that the two systems that have been licensed to use are Spectra Optia Apheresis System and Depuro D2000 Adsorption Cartridge and produced by Terumo BCT Inc and Marker Therapeutics AG.